[HTML][HTML] IUPHAR review-Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
VIN Bruns, EH Tressler, LF Vendruscolo… - Pharmacological …, 2024 - Elsevier
Addiction is a chronic relapsing disease with high morbidity and mortality. Treatments for
addiction include pharmacological and psychosocial interventions; however, currently …
addiction include pharmacological and psychosocial interventions; however, currently …
Targeting GLP-1 Receptors to Reduce Nicotine Use Disorder: Preclinical and Clinical Evidence
RJ Herman, HD Schmidt - Physiology & Behavior, 2024 - Elsevier
Nicotine use disorder (NUD) remains a leading cause of preventable death in the US
Unfortunately, current FDA-approved pharmacotherapies for smoking cessation have limited …
Unfortunately, current FDA-approved pharmacotherapies for smoking cessation have limited …
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
S Tempia Valenta, A Nicastri, F Perazza… - … Treatment Options in …, 2024 - Springer
Purpose Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for
managing metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Beyond …
managing metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Beyond …
The effect of glucagon-like peptide 1 receptor agonists on alcohol and tobacco craving among patients with type 2 diabetes mellitus: a cross-sectional, questionnaire …
J Budzyński, D Czarnecki… - Medical Research …, 2024 - journals.viamedica.pl
Introduction: Glucagon-like peptide 1 receptor (GLP-1R) agonists are widely used in therapy
for type 2 diabetes mellitus (DM2) and obesity. There are also increasing amounts of data …
for type 2 diabetes mellitus (DM2) and obesity. There are also increasing amounts of data …